Boehringer Ingelheim has concluded phase one of their localization effort aimed at manufacturing their innovative thrombolytic medicines in Russia: the first batches of Metalyse (tenectaplase) for acute heart attack treatment were produced at NPO Petrovax Pharm facilities.

By the end of 2019, the companies intend to complete the transfer of technologies and to launch full-cycle production of innovative thrombolytic medicines at Petrovax Pharm’s production facility in the Moscow Region.

Vladimir Potanin, the owner and founder of Interros Group, one of the largest private investment companies in Russia, has completed acquisition of a controlling stake in Petrovax Pharm. For more details please visit www.petrovax.com